Related Experiment Video
Updated: Jun 29, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification
Lijuan Weng1,2, Jianliang Zhou2, Shenchao Guo2
1Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Abstract:
Triple-negative breast cancer (TNBC) is widely recognized as the most aggressive form of breast cancer, occurring more frequently in younger patients and characterized by high heterogeneity, early distant metastases and poor prognosis. Multiple treatment options have failed to achieve the expected therapeutic effects due to the lack of clear molecular targets. Based on genomics, transcriptomics and metabolomics, the multi-omics analysis further clarifies TNBC subtyping, which provides a greater understanding of tumour heterogeneity and targeted therapy sensitivity. For instance, the luminal androgen receptor subtype (LAR) exhibits responsiveness to anti-AR therapy, and the basal-like immune-suppressed subtype (BLIS) tends to benefit from poly (ADP-ribose) polymerase inhibitors (PARPis) and anti-angiogenic therapy. The efficacy of multi-dimensional combination therapy holds immense importance in guiding personalized and precision medicine for TNBC. This review offers a systematic overview of recent FuDan TNBC molecular subtyping and its role in the instruction of clinical precision therapy.
Insights
Triple-negative breast cancer (TNBC) is aggressive and lacks molecular targets. Multi-omics analysis refines TNBC subtypes, guiding precision medicine and improving treatment strategies for better patient outcomes.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Triple-negative breast cancer (TNBC) is an aggressive malignancy with high heterogeneity, early metastasis, and poor prognosis.
- Current treatments are limited by the lack of specific molecular targets, hindering therapeutic efficacy.
Purpose of the Study:
- To provide a systematic overview of recent FuDan TNBC molecular subtyping.
- To elucidate the role of multi-omics analysis in understanding TNBC heterogeneity and guiding precision therapy.
Main Methods:
- Integration of genomics, transcriptomics, and metabolomics data for multi-omics analysis.
- Classification of TNBC into distinct molecular subtypes based on comprehensive data.
Main Results:
- Multi-omics analysis refines TNBC subtyping, enhancing understanding of tumor heterogeneity.
- Specific subtypes like Luminal Androgen Receptor (LAR) show sensitivity to anti-AR therapy.
- Basal-like Immune-Suppressed (BLIS) subtypes may benefit from PARP inhibitors and anti-angiogenic therapy.
Conclusions:
- Molecular subtyping of TNBC is crucial for identifying targeted therapy sensitivities.
- Multi-dimensional combination therapies informed by molecular subtypes are essential for personalized and precision medicine in TNBC.
- This review highlights the clinical implications of FuDan TNBC molecular subtyping for precision treatment strategies.
More Related Videos
11:12Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016